Background Low-dose naltrexone (LDN) is used widely as an off-label treatment for pain
despite limited evidence for its effectiveness. A few small trials with a high risk of bias have …

Background Low-dose naltrexone is used to treat fibromyalgia despite minimal evidence for
its efficacy. This trial aimed to investigate whether 12-week treatment with 6 mg low-dose …

Objective To determine whether low dosages (4.5 mg/day) of naltrexone reduce
fibromyalgia severity as compared with the nonspecific effects of placebo. In this replication …

Fibromyalgia (FM) is a chronic pain sensitivity syndrome characterized by diffuse
musculoskeletal pain and many other systemic manifestations. Low-dose naltrexone (LDN) …

Objective This study explores dose–response relationships when treating fibromyalgia with
low-dose naltrexone. Design A single-blinded clinical trial was carried out using the “up-and …

Introduction There is evidence that low-dose naltrexone (LDN;< 5.0 mg/day) reduces pain
and improves the quality of life of people with fibromyalgia syndrome (FMS). However, no …

Despite its prevalence, there is no clear-cut diagnostic path or treatment paradigm for
fibromyalgia; this can lead to a multiplicity of symptoms and comorbid conditions that …

Background: ConclusionFibromyalgia is a chronic pain disorder characterized by diffuse
musculoskeletal pain, fatigue, sleep disturbance and cognitive impairment. Objective: A …

Background and objective Fibromyalgia is characterised by chronic, widespread
musculoskeletal pain and other systemic symptoms. Current pharmaceutical intervention …

Objectives: First, to examine if LDN is associated with analgesic efficacy compared with
control in the treatment of patients with FM. Second, to ascertain the analgesic efficacy of …